Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Windtree Therapeutics Inc (NQ: WINT )

0.9003 +0.0003 (+0.03%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 301
Open 0.9003
Bid (Size) 0.8600 (7)
Ask (Size) 0.9150 (5)
Prev. Close 0.9000
Today's Range 0.9003 - 0.9003
52wk Range 0.8605 - 21.00
Shares Outstanding 5,148,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
Via ACCESSWIRE

Performance

YTD
-89.88%
-89.88%
1 Month
-17.40%
-17.40%
3 Month
-29.66%
-29.66%
6 Month
-80.47%
-80.47%
1 Year
-94.15%
-94.15%

More News

Read More
Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
Via Benzinga
How Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators
Via Benzinga
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
Via ACCESSWIRE
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
Via ACCESSWIRE
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
Via Benzinga
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That
Via ACCESSWIRE
Windtree Therapeutics – This Biotech Is Developing Drugs For Patients In Crisis
Via Benzinga
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Nasdaq Down 100 Points; American Express Earnings Miss Views
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Crude Oil Down 2%; AT&T Shares Plunge After Q1 Results
Via Benzinga
Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Tumbles 150 Points; Tesla Shares Drop After Q1 Results
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why Is Bed Bath & Beyond (BBBY) Stock Down 19% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.